FIELD: biotechnology.
SUBSTANCE: a mutant fully human antibody against HER2 is described, wherein the amino acid sequence of the heavy chain variable region and the amino acid sequence of the antibody light chain variable region are SEQ ID NO: 10 and SEQ ID NO: 2; SEQ ID NO: 11 and SEQ ID NO: 2; or SEQ ID NO: 12 and SEQ ID NO: 2, respectively. Also, a nucleic acid encoding the described antibody is provided. A vector comprising such an acid. A composition containing the described antibody.
EFFECT: invention can be used in combination with additional therapeutic agents against HER2-positive tumors to treat an HER2-positive tumor, a weakly positive tumor, and a negative tumor.
9 cl, 13 dwg, 6 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BINDING MOLECULE SPECIFIC FOR HER3, AND THEIR APPLICATIONS | 2012 |
|
RU2620068C2 |
| ALLOSTERIC ANTIBODIES AGAINST HUMAN HER3 NON COMPETITIVE FOR NEUREGULIN AND USE THEREOF | 2013 |
|
RU2704228C2 |
| COMPOSITION CONTAINING ANTIBODY BINDING TO DOMAIN II OF HER2, AND ITS ACIDIC VERSIONS | 2009 |
|
RU2543664C2 |
| ANTI-HER2 ANTIBODY AND CONJUGATE THEREOF | 2014 |
|
RU2656161C1 |
| INTRODUCTION OF FIXED DOSES OF HER-ANTIBODIES | 2005 |
|
RU2438705C2 |
| COMPOSITION OF HER2 ANTIBODIES | 2005 |
|
RU2361880C2 |
| ANTIBODIES, CAPABLE OF SPECIFIC CONNECTING WITH HER2 | 2014 |
|
RU2628094C2 |
| COMPOSITIONS OF ANTIBODIES | 2005 |
|
RU2426554C2 |
| MULTISPECIFIC ANTIBODIES, THEREOF ANALOGUES, COMPOSITIONS AND METHODS | 2010 |
|
RU2580038C2 |
| IDENTIFICATION OF PATIENTS IN NEED OF COMBINED THERAPY WITH PD-L1 INHIBITOR | 2013 |
|
RU2692773C2 |
